Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. (nejm.org)

Authors: Galsky MD … Gomez de Liano A Journal: New England Journal of Medicine Published: 2026-07-23 DOI: https://doi.org/10.1056/NEJMoa2601486